| abstract |
The invention comprises (a) at least one antibody molecule (e.g., a humanized antibody molecule) that binds to Programmed Death 1 (PD-1), and (b) an HDM2-p53 interaction inhibitor, , A pharmaceutical combination for administration simultaneously, individually or sequentially for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination; A method of treating a subject suffering from a proliferative disease comprising administering the combination to a subject in need thereof; The use of such combinations for the treatment of proliferative diseases; And it relates to a commercial package containing such a combination; The proliferative disease is a TP53 wild-type tumor, especially TP53 wild-type renal cell carcinoma (RCC) or TP53 wild-type colorectal cancer (CRC). |